pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,525 catalysts · 4,728 grant · 3,076 device 510k · 3,045 8k filing · 2,774 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2025-05-02×clear all
type
  • grant4,728
  • device 510k3,076
  • 8k filing3,045
  • approval2,774
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall751
  • earnings579
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Apr 28, 2025

    1
    ›May 2, 2025approval466d agoTICAGRELOR — FDA approvalTICAGRELOR

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →TICAGRELOR →fda approvals ↗

    Week of May 5, 2025

    19
    ›May 5, 2025approval463d agoTICAGRELOR — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›May 5, 2025approval463d agoFENSOLVI KIT (LEUPROLIDE ACETATE) — FDA approvalLEUPROLIDE ACETATE

    Sponsor: TOLMAR. Form: POWDER. Route: SUBCUTANEOUS

    full page →LEUPROLIDE ACETATE →fda approvals ↗
    ›May 6, 2025approval462d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›May 7, 2025approval461d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →risankizumab →fda approvals ↗
    ›May 7, 2025approval461d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

    full page →risankizumab →fda approvals ↗
    ›May 7, 2025recall461d agoACCORD HEALTHCARE, INC. recall (Cls II)HCA Healthcare, Inc.

    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-450-17 — Reason: Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoCardinal Health Inc. recall (Cls II)CARDINAL HEALTH INC

    Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. — Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoEugia US LLC recall (Cls II)Eugia US LLC

    Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01 — Reason: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoAmerican Regent, Inc. recall (Cls II)American Regent Inc

    niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial, Rx Only, Mfd for: Civica, Inc., Lehi, UT 84043,Mfd by: American Regent, Inc., New Albany, OH 43064. NDC Carton: 72572-470-10/ NDC Vial: 72572-470-01. — Reason: Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoEugia US LLC recall (Cls II)Eugia US LLC

    Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-429-01 — Reason: Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoNubratori, Inc recall (Cls II)Taiwan Liposome Co Ltd

    Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free, For Iontophoresis Use Only, Non-Sterile Product, Not for Injection, NUBRATORI RX, 381 Van Ness Ave# 1507, CA 90501, NDC 71300-6564-1 (box), 71300-6564-3 (vial). — Reason: Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoACCORD HEALTHCARE, INC. recall (Cls II)HCA Healthcare, Inc.

    Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 90 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-452-15 — Reason: Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoMckesson Medical-Surgical Inc. Corporate Office recall (Cls II)Baxter Healthcare Corp

    Infuvite Adult, multiple vitamins injection, Baxter, Five of Vial 1 (5 mL) and Five of Vial 2 (5mL), Rx Only, Sterile, Manufactured for: Sandoz Inc., Princeton, NJ 08540, Distributed by Baxter Healthcare Corporation, Deerfield, IL 60015 USA, Product of Canada, NDC 54643-5649-1 — Reason: Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoAmerican Regent, Inc. recall (Cls II)American Regent Inc

    niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial, Rx Only, American Regent, Inc., Shirley, NY 11967. NDC carton: 0517-0735-10 / NDC Vial: 0517-0735-01] — Reason: Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoPreferred Pharmaceuticals, Inc. recall (Cls II)InMed Pharmaceuticals Inc.

    Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03. — Reason: cGMP Deviations — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoACCORD HEALTHCARE, INC. recall (Cls II)HCA Healthcare, Inc.

    Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-448-17. — Reason: Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoMckesson Medical-Surgical Inc. Corporate Office recall (Cls II)Eugia US LLC

    Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg / mL, 1 mL Single-Dose Vial, Rx only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520, NDC 55150-0330-01 — Reason: Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product. — Status: Ongoing

    full page →fda recalls ↗
    ›May 7, 2025recall461d agoACCORD HEALTHCARE, INC. recall (Cls II)HCA Healthcare, Inc.

    Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-447-17 — Reason: Subpotent — Status: Ongoing

    full page →fda recalls ↗
    ›May 9, 2025approval459d agoBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalNovitium Pharma LLC

    Sponsor: LGM PHARMA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗

    Week of May 12, 2025

    21
    ›May 12, 2025approval456d agoINREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approvalfedratinib

    Sponsor: BRISTOL-MYERS. Form: CAPSULE. Route: ORAL

    full page →fedratinib →fda approvals ↗
    ›May 12, 2025approval

    Week of May 19, 2025

    9
    ›May 19, 2025approval449d agoSUBOXONE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: INDIVIOR. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 19, 2025approval
    ← prev
    page 1 of 71
    next →
    456d ago
    TYENNE (TOCILIZUMAB-AAZG) — FDA approvalTYENNE

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INTRAVENOUS

    full page →TYENNE →fda approvals ↗
    ›May 14, 2025approval454d agoKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvaltrastuzumab emtansine

    Sponsor: GENENTECH. Form: VIAL. Route: SINGLE-USE

    full page →trastuzumab emtansine →fda approvals ↗
    ›May 14, 2025approval454d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›May 14, 2025recall454d agoSiddha Flower Essences, LLC. recall (Cls II)

    temper tamer, 1 US fl oz. (29.6 mL), Homeopathic Oral Spray, Manufactured by: Siddha Flower Essences, Oxnard, CA, 93030 NDC 69779-020-01. — Reason: CGMP Deviations — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoRemedyRePack Inc. recall (Cls II)RemedyRepack Inc

    Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsules per bottle, Rx Only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. NDC#: 70518-3772-02 — Reason: CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBRS Analytical Services, LLC recall (Cls II)

    Artificial Tears Ophthalmic Solution, Dextran 70.01%/Glycerin 0.2%/Hypromellose 0.3% (Eye Lubricants) Lubricant Eye Drops, STERILE, 0.5 FL OZ (15 mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-043-15. — Reason: cGMP deviations and lack of assurance of sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoFDC Limited recall (Cls II)FDC Ltd

    Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 10mL bottles, Rx only, Manufactured by: FDC Limited, Waluj, Aurangabad, Maharashtra, India, Distributed by: Rising Pharmaceuticals Inc, New Jersey, NDC 64980-514-01. — Reason: Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoAmneal Pharmaceuticals, LLC recall (Cls I)Amneal Pharmaceuticals, Inc.

    Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box) — Reason: Presence of Particulate Matter — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBSO LLC recall (Cls II)Transdermal Delivery Solutions Corp

    TESTOSTERONE PELLET 100 mg (with Cholesterol </=4%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug, Not for Resale, RX or Office Use Only, Belmar Select Outsources, 12860 W. Cedar Drive #211, Lakewood, CO 80228, NDC: 70168-0101-01 — Reason: Presence of Particulate Matter: Glass particles were found in pellet vials. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBRS Analytical Services, LLC recall (Cls II)Dr Rajendra Prasad Centre for Ophthalmic Sciences

    Carboxymethylcellulose Sodium Ophthalmic Gel 1%, Carboxymethlycellulose Sodium 1% Eye Lubricant, Lubricant Eye Gel, Soothing Gel, Sterile, 0.5 FL OZ (15mL) per bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-066-15. — Reason: cGMP deviations and lack of assurance of sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBSO LLC recall (Cls II)Transdermal Delivery Solutions Corp

    TESTOSTERONE PELLET 200 mg BLUNT, 1 Pellet for Subcutaneous Use, This is a Compounded Drug, Not for Resale, RX or Office Use Only, Belmar Select Outsources, 12860 W. Cedar Drive #211, Lakewood, CO 80228, NDC: 70168-0121-01 — Reason: Presence of Particulate Matter: Glass particles were found in pellet vials. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoApollo Care, LLC recall (Cls II)Revalesio Corp

    FentaNYL 500mcg (2mcg/mL) and Ropivacaine HCl 250mg (0.1%) added to 250 mL, 0.9% Sodium Chloride Injection (For Epidural Use Only), Sterile, Single-Use Container, Rx Only, Apollocare, 3801 Mojave Ct, Ste 101, Columbia, MO 65202, NDC 71170-950-25 — Reason: Lack of Assurance of Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBRS Analytical Services, LLC recall (Cls II)

    Polyvinyl Alcohol Ophthalmic Solution 1.4%, Lubricant Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-678-15. — Reason: cGMP deviations and lack of assurance of sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBSO LLC recall (Cls II)Transdermal Delivery Solutions Corp

    TESTOSTERONE PELLET 200 mg (with Cholesterol </=4%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug, Not for Resale, RX or Office Use Only, Belmar Select Outsources, 12860 W. Cedar Drive #211, Lakewood, CO 80228, NDC: 70168-0122-01 — Reason: Presence of Particulate Matter: Glass particles were found in pellet vials. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBRS Analytical Services, LLC recall (Cls II)

    Lubricant Eye Drops Solution, Polyethylene Glycol 400 0.4% Eye Lubricant, Propylene Glycol 0.3% Eye Lubricant, Lubricant Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-126-15. — Reason: cGMP deviations and lack of assurance of sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBSO LLC recall (Cls II)Transdermal Delivery Solutions Corp

    TESTOSTERONE PELLET 200 mg BLUNT (with Cholesterol </=2%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug, Not for Resale, RX or Office Use Only, Belmar Select Outsources, 12860 W. Cedar Drive #211, Lakewood, CO 80228, NDC: 70168-0124-01 — Reason: Presence of Particulate Matter: Glass particles were found in pellet vials. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBRS Analytical Services, LLC recall (Cls II)Dr Rajendra Prasad Centre for Ophthalmic Sciences

    Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%, Carboxymethlycellulose Sodium 0.5% Eye Lubricant, Lubricating Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-068-15. — Reason: cGMP deviations and lack of assurance of sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›May 14, 2025recall454d agoBSO LLC recall (Cls II)Transdermal Delivery Solutions Corp

    TESTOSTERONE PELLET 200 mg (with Cholesterol </=2%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug, Not for Resale, RX or Office Use Only, Belmar Select Outsources, 12860 W. Cedar Drive #211, Lakewood, CO 80228, NDC: 70168-0125-01 — Reason: Presence of Particulate Matter: Glass particles were found in pellet vials. — Status: Ongoing

    full page →fda recalls ↗
    ›May 15, 2025approval453d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›May 15, 2025approval453d agoZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalretifanlimab

    Sponsor: INCYTE CORP. Form: INJECTABLE. Route: INTRAVENOUS

    full page →retifanlimab →fda approvals ↗
    449d ago
    ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalEdenbridge Pharmaceuticals LLC

    Sponsor: EDENBRIDGE PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 20, 2025approval448d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›May 20, 2025approval448d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

    Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

    full page →CYLTEZO →fda approvals ↗
    ›May 20, 2025approval448d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›May 21, 2025approval447d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›May 21, 2025approval447d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›May 21, 2025approval447d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›May 21, 2025approval447d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    $ABBV247.97+0.78%
    $HCA414.03+0.16%
    $ABBV247.97+0.78%
    $HCA414.03+0.16%
    $CAH237.18+0.33%
    $INM1.4100-4.08%
    $HCA414.03+0.16%
    $HCA414.03+0.16%
    $BMY64.84+0.19%
    $INDV38.47-0.90%
    $AMRX17.88-1.43%
    $INCY121.55+0.82%
    $AMGN417.20+1.52%